Yesterday, the President and General Counsel of Amphastar Pharmaceuticals (AMPH), Jason Shandell, sold shares of AMPH for $973.9K.
See today’s analyst top recommended stocks >>
Based on Amphastar Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $89.69 million and quarterly net profit of $1.87 million. In comparison, last year the company earned revenue of $60.4 million and had a net profit of $1.47 million. Currently, Amphastar Pharmaceuticals has an average volume of 258.3K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $24.67, reflecting a 21.1% upside.
The insider sentiment on Amphastar Pharmaceuticals has been negative according to 62 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.
